Posted On: 12/05/2016 2:49:30 PM
Post# of 72447
Thanks for the link. So no mention of K or Cellceutix in the article specifically but there was this one nugget:
"Amaro's work illustrates how a handful of academic labs and small companies are making progress with a fresh approach to targeting p53: rescuing it when it's sick. They're finding drugs that bind to and prop up copies of mutated p53, restoring its shape and ability to carry out its job. One such drug has already passed an early stage safety trial in humans, and a more advanced clinical trial is now underway in Europe. Other would-be medicines are nearing human tests. If any succeed in the clinic, they could dramatically change the landscape for cancer treatment—and for other diseases that involve misfolded proteins, perhaps even Alzheimer's."
Is that a reference to CTIX? I cant recall if the K Ovarian Phase 2 trial was going to be in the states or not. The FDA is going to approve the trial design and protocol regardless, but it escapes me if they were trying to get it abroad to save costs or not. Sox, do you remember?
"Amaro's work illustrates how a handful of academic labs and small companies are making progress with a fresh approach to targeting p53: rescuing it when it's sick. They're finding drugs that bind to and prop up copies of mutated p53, restoring its shape and ability to carry out its job. One such drug has already passed an early stage safety trial in humans, and a more advanced clinical trial is now underway in Europe. Other would-be medicines are nearing human tests. If any succeed in the clinic, they could dramatically change the landscape for cancer treatment—and for other diseases that involve misfolded proteins, perhaps even Alzheimer's."
Is that a reference to CTIX? I cant recall if the K Ovarian Phase 2 trial was going to be in the states or not. The FDA is going to approve the trial design and protocol regardless, but it escapes me if they were trying to get it abroad to save costs or not. Sox, do you remember?
(0)
(0)
